

## February 2017 – cCOG meeting

2017 Meeting Summary - Thursday 2 February, presenters detailed below have given consent to be contacted for more information in relation to their topics:

- [Simon Denegri](#), NIHR National Director for Patients and Public, presented details of the May 2017 International Clinical Trials Day and the UK Clinical Trials Gateway.  
[Briefing on the NIHR International Clinical Trials Day](#) (pdf)
- Alastair Nicholson, HRA Policy Development Lead, provided updates on the mCTA development and the implications of MIA on clinical research and loaned equipment in England.
- [Dr Steve McSwiggan](#), Head of Commercial Research Services, Tayside Medical Sciences Centre, presented a review including how commercial SIVs are received at the Dundee clinical trial unit –

*'Ten Site Initiation Visits (SIV) conducted between Sept and Dec 2016 for commercial trials commencing in NHS Tayside were reviewed for number of staff attending, duration of visit, cost to NHS to accommodate and whether the Regulatory Green Light to commence recruitment followed soon after the SIV. Presenters were also rated by those attending the SIV.*

*The review was conducted as the efficiencies we have demonstrated in study review times [in Scotland] have largely not translated into more rapid site set up. We set out to get some baseline data on SIVs and to determine if 'preparedness to start' the study could be improved. In today's tight financial climate we require some evidence and understanding of the real costs to the NHS of delivering clinical trials and set out to examine that by looking at how we accommodate SIVs as it is a relatively simple and controlled metric to calculate.'*

- [Lydia Vitolo](#), Senior Industry Manager, and [Steven Burke](#), Industry Liaison Manager presented updates for Health and Care Research Wales and NHS Research Scotland respectively.
- [Lorraine Fincham](#), Commercial Research Initiative Manager, presented an NIHR update including details of a single feasibility service which would include England and the devolved administrations. **Companies should continue to approach individual devolved administrations until the system is up and running.**
- cCOG members confirmed 2017 objectives:
  - Site Readiness and Activation (NEW)
  - Raising Patient and Public Awareness of Clinical Trials (ongoing)
  - Data Quality in Clinical Trials (ongoing)
  - Support optimal Clinical Trial Conduct in the UK through a rapid, smooth and clear HRA approval process both at study set up and amendments approvals (expanded from 2016)

Next meeting 23 June 2017